CPSE:HLUN BPharmaceuticals
Assessing H. Lundbeck (CPSE:HLUN B) Valuation After South Korean Approval Of Eptinezumab
H. Lundbeck (CPSE:HLUN B) is back on investors’ radar after South Korea’s Ministry of Food and Drug Safety granted marketing authorization for eptinezumab, its intravenous anti-CGRP preventive migraine treatment for adults.
See our latest analysis for H. Lundbeck.
The eptinezumab approval lands at a time when Lundbeck’s DKK42.84 share price has a 90 day share price return of 11.62%, while the 1 year total shareholder return of 21.57% points to momentum that has built over a longer period...